A Comparison of Pharmacokinetic Models of Dynamic Contrast Enhanced MRI

Authors:
Rujirutana Srikanchana;David Thomasson;Peter Choyke;Andrew Dwyer
Affiliations:
National Cancer Institute, Bethesda, MD;National Institutes of Health, Bethesda, MD;National Cancer Institute, Bethesda, MD;National Institutes of Health, Bethesda, MD
Venue:
CBMS '04 Proceedings of the 17th IEEE Symposium on Computer-Based Medical Systems
Year:
2004

Citing 0
Cited 3

Pharmacokinetic Perfusion Curves Estimation for Liver Tumor Diagnosis from DCE-MRI

ICIAR '08 Proceedings of the 5th international conference on Image Analysis and Recognition
Prostate cancer localization with multispectral MRI using cost-sensitive support vector machines and conditional random fields

IEEE Transactions on Image Processing
T1 mapping, AIF and pharmacokinetic parameter extraction from dynamic contrast enhancement MRI data

MBIA'11 Proceedings of the First international conference on Multimodal brain image analysis

Quantified Score

Hi-index	0.00

Visualization

Abstract

Dynamic Contrast Enhanced MRI (DCE-MRI) is often employed as an indicator of drugactivity in clinical trials of angiogenic inhibitors. The data obtained with DCE-MRI isreported semi quantitatively using parameters derived from pharmacokinetic models. MostMRI kinetic models were developed from Nuclear Medicine quantitative studies but thelimitations of MRI dictated specific modifications. A number of these MRI models are incurrent use. In this work, we review several pharmacokinetic models used in DCE-MRI inorder to determine the most appropriate model to assess tumor angiogenesis. These modelsare compared with respect to their physiological appropriateness; compartmental analysis;initial and boundary conditions; and clinically relevant output parameters.